Gliomas molecular markers: importance in treatment, prognosis and applicability in brazilian health system

Abstract

Gliomas represent 80% of all primary malignant brain tumors in adults. In view of this public health problem, the early detection through sensitive and specifi c molecular tumor markers analysis can help to improve gliomas diagnosis and prognosis as well as their staging, assessment of therapeutic response and detection of recurrence. Therefore, this review focuses in current gliomas tumor markers, IDH-1/2, 1p/19q, MGMT, ATRX, TERT, H3, EGFR, BRAF and Ki67 used in clinic worldwide and their importance to early detection, glioma histological and molecular classifi cation as well as in predicting patient's therapeutic response. In addition, we present what are the steps in the requesting process for this type of examination in the Brazilian Public Health System (SUS) scope, which attends most of the Brazilian population. Thereby, this article is useful in demonstrating which markers are used in the clinical practice for glioma patients and can be performed in the SUS through partnerships/agreements between specialized health centers and clinical analysis laboratories. It is hoped that this work clarifi es, the necessary subsidies to carry out the research of tumor markers in all institutions that serve SUS users, providing a service with equal conditions.

Integrated analysis reveals CP is a potential biomarker and therapeutic target in glioma

“…Consequently, we hypothesized that elevated CP expression levels might contribute to the progression of glioma. Additionally, studies have demonstrated the signi cance of 1p19q co-deletion and IDH mutation status in predicting glioma prognosis, as patients with these genetic characteristics typically exhibit a more favorable outcome(Di Nunno et al, 2022;Soldatelli et al, 2022). Furthermore, our results indicate low CP expression levels in glioma patients with 1p19q codeletion and IDH mutation.…”

Homeostatic status of thyroid hormones and brain water movement as determinant factors in biology of cerebral gliomas: a pilot study using a bioinformatics approach

“…In addition, both AQP1 and AQP4 showed a significant difference in expression pattern upon comparison with tumor markers/antigens in gliomas that are consensually used in clinical practice to establish degrees of malignancy and prognosis ( Soldatelli et al, 2022 ). For instance: TP53, ATRX, TERT, IDH1, EGFR, and GFAP ( Figure 4 ).…”